<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631667</url>
  </required_header>
  <id_info>
    <org_study_id>LPI-8554</org_study_id>
    <secondary_id>R01ES028600</secondary_id>
    <nct_id>NCT03631667</nct_id>
  </id_info>
  <brief_title>Ultralow Dose PAH Binary Mixture Study</brief_title>
  <official_title>Ultralow Dose PAH Binary Mixture Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Environmental Health Sciences (NIEHS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lawrence Livermore National Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pacific Northwest National Laboratory</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the pharmacokinetics for [14C]-benzo[a]pyrene ([14C]-BaP) and metabolites in
      plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng
      phenanthrene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pharmacokinetics for [14C]-BaP and metabolites will be assessed by UHLPC-Accelerator Mass
      Spectrometry (AMS, Lawrence Livermore National Laboratory) in plasma and urine collected over
      48 hours following oral doses of 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.
      Metabolite profiles and kinetics of elimination are predicted to be consistent with a BaP
      physiologically based pharmacokinetic (PBPK) model developed by Pacific Northwest National
      Laboratory (PNNL). A non-smoker, not exposed occupationally, receives 270-700 ng of BaP
      daily; about 95% dietary. The WHO has set an estimated safe daily lifetime (70 year/70 Kg
      individual, cancer endpoint) exposure to BaP of 42-350 ng. This protocol represents de
      minimus risk.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Deidentified samples will be analyzed by AMS at Lawrence Livermore National Laboratory and the pharmacokinetics determine at Pacific Northwest National Laboratory.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma and urine 14C-BaP and 14C-BaP metabolite levels after oral dose</measure>
    <time_frame>48 hours</time_frame>
    <description>Plasma and urine levels of 14C-BaP and 14C-BaP metabolites measured by accelerator mass spectrometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration of 14C-BaP Cmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Determination of highest concentration of 14C-BaP in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at highest plasma concentration of 14C-BaP Tmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Determination of time at which plasma concentration of 14C-BaP is highest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration of 14C-BaP versus time curve AUC</measure>
    <time_frame>48 hours</time_frame>
    <description>Integration of concentration of 14C-BaP in plasma over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of elimination of 14C-BaP</measure>
    <time_frame>48 hours</time_frame>
    <description>Determination of constants for rate of elimination of 14C-BaP from plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites of 14C-BaP in plasma</measure>
    <time_frame>48 hours</time_frame>
    <description>Determination of plasma metabolites of 14C-BaP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites of 14C-BaP in urine</measure>
    <time_frame>48 hours</time_frame>
    <description>Determination of urinary metabolites of 14C-BaP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Environmental Exposure</condition>
  <arm_group>
    <arm_group_label>50 ng dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 ng dose plus 1250 ng phenanthrene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP) and 1250 phenanthrene</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-benzo[a]pyrene</intervention_name>
    <description>Oral micro-dose (50 ng) (5.4 nCi)</description>
    <arm_group_label>50 ng dose</arm_group_label>
    <other_name>Carcinogenic PAH environmental pollutant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-benzo[a]pyrene plus phenanthrene</intervention_name>
    <description>Oral micro-dose of 50 ng (5.4 nCi) [14C]-benzo[a]pyrene plus 1250 ng phenanthrene</description>
    <arm_group_label>50 ng dose plus 1250 ng phenanthrene</arm_group_label>
    <other_name>Binary mixture of carcinogenic PAH and non-carcinogenic PAH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21-65 (inclusive)

          -  If female, must be post-menopausal or have had surgical sterilization to eliminate any
             possibility for fetal exposure

          -  Willing to defer blood donation for one month before, throughout, and one month after
             completion of study activities

          -  Willing to avoid consuming cruciferous vegetables, I3C or DIM supplements, smoked or
             cured meat or cheeses, or charcoal-grilled meats for 2 weeks prior to and during each
             study cycle (gas grilled foods acceptable)

        Exclusion Criteria:

          -  Smoker (tobacco or other substances) or use of smokeless tobacco in past 3 months or
             living with smoker

          -  Regular use of medications that affect gut motility or nutrient absorption (e.g.
             cholestyramine, sucralfate, orlistat, pro- or anti-motility agents)

          -  History of gastrointestinal surgery (e.g. bariatric surgery, cholecystectomy) or
             gastrointestinal disorder (Crohn's disease, celiac disease, IBS, or colitis)

          -  Current or history of kidney or liver disease

          -  Prior high-dose 14C exposure from medical tests. (micro-dose 14C exposure not
             exclusionary)

          -  Occupational PAH exposure (e.g. roofers, asphalt pavers, fire-fighters, etc.)

          -  Regular use of indole-3-carbinol or DIM dietary supplements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oregon State University</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon State University</investigator_affiliation>
    <investigator_full_name>David Williams</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Benzo[a]pyrene</keyword>
  <keyword>Accelerator Mass Spectrometry</keyword>
  <keyword>Polycyclic Aromatic Hydrocarbons</keyword>
  <keyword>Phenanthrene</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Deidentified samples sent to Lawrence Livermore National Laboratory Deidentified data sent to Pacific Northwest National Laboratory</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

